Literature DB >> 18090547

Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans.

Markus P Schlaich1, Dominik Schmitt, Christian Ott, Bernhard Mw Schmidt, Roland E Schmieder.   

Abstract

BACKGROUND: Experimental data suggest that increased nitric oxide synthase (NOS) activity contributes to preglomerular vasodilation and subsequent glomerular hyperfiltration. Whether such a relationship also exists in the human renal vasculature has not yet been adequately determined. METHODS AND
RESULTS: We assessed systemic, renal, and intragomerular haemodynamics in 310 subjects with normal renal function [glomerular filtration rate (GFR) > 60 ml/min per 1.73 m], before and after NOS inhibition with L-Nmonomethyl arginine (L-NMMA). Subjects were arbitrarily divided into tertiles according to their basal NOS activity, as assessed by the decrease in renal plasma flow in response to L-NMMA (high -23.4 +/- 8.1 versus medium -10.8 +/- 2.2 versus low -1.0 +/- 4.8%). Resting GFR differed significantly between tertiles: high 114 +/- 21 versus medium 109 +/- 19 versus low 104 +/- 21 ml/min per 1.73 m; analysis of variance P = 0.003. In a multiple stepwise regression analysis, basal NOS activity was the major factor to explain resting GFR (beta = -0.344; P < 0.001). Body weight (beta = -0.295; P < 0.001) and age (beta = -0.164; P < 0.001) emerged as additional factors, whereas body mass index and blood pressure did not enter the final model. The close relationship between resting GFR and basal NOS activity was also mirrored in the renal microcirculation, as demonstrated by an exaggerated effect of L-NMMA on the increase in arteriolar resistance, particularly that of the afferent (RA) arteriole, with higher basal nitric oxide (NO) activity (RA: high +1542 +/- 1065 versus medium +1024 +/- 718 versus low +675 +/- 861 dyne/s per cm; P < 0.001).
CONCLUSION: Our data clearly support experimental evidence linking NOS activity with increased glomerular filtration, and suggest that basal NO activity is also a major determinant of glomerular haemodynamics in the human renal vasculature.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18090547     DOI: 10.1097/HJH.0b013e3282f1a93e

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  9 in total

1.  Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial.

Authors:  Yuzuru Kanakura; Kazuma Ohyashiki; Tsutomu Shichishima; Shinichiro Okamoto; Kiyoshi Ando; Haruhiko Ninomiya; Tatsuya Kawaguchi; Shinji Nakao; Hideki Nakakuma; Jun-ichi Nishimura; Taroh Kinoshita; Camille L Bedrosian; Marye Ellen Valentine; Gus Khursigara; Keiya Ozawa; Mitsuhiro Omine
Journal:  Int J Hematol       Date:  2011-01-12       Impact factor: 2.490

2.  Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial.

Authors:  Christian Ott; Iris Kistner; Mirjam Keller; Stefanie Friedrich; Carsten Willam; Peter Bramlage; Roland E Schmieder
Journal:  Diabetologia       Date:  2016-09-01       Impact factor: 10.122

Review 3.  A conceptual framework for the molecular pathogenesis of progressive kidney disease.

Authors:  H William Schnaper; Susan C Hubchak; Constance E Runyan; James A Browne; Gal Finer; Xiaoying Liu; Tomoko Hayashida
Journal:  Pediatr Nephrol       Date:  2010-03-30       Impact factor: 3.714

4.  Low molecular weight heparin mediated regulation of nitric oxide synthase during burn wound healing.

Authors:  R T S Lakshmi; T Priyanka; J Meenakshi; K R Mathangi; V Jeyaraman; M Babu
Journal:  Ann Burns Fire Disasters       Date:  2011-03-31

Review 5.  The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.

Authors:  Keizo Kanasaki
Journal:  Clin Sci (Lond)       Date:  2018-02-28       Impact factor: 6.124

6.  Pioglitazone in diabetic kidney disease: forgotten but not gone.

Authors:  Georgios S Papaetis
Journal:  Arch Med Sci Atheroscler Dis       Date:  2022-08-08

7.  ARA290, a non-erythropoietic EPO derivative, attenuates renal ischemia/reperfusion injury.

Authors:  Willem G van Rijt; Gertrude J Nieuwenhuijs-Moeke; Harry van Goor; Bente Jespersen; Petra J Ottens; Rutger J Ploeg; Henri G D Leuvenink
Journal:  J Transl Med       Date:  2013-01-09       Impact factor: 5.531

8.  L-Arginine Supplementation in Type II Diabetic Rats Preserves Renal Function and Improves Insulin Sensitivity by Altering the Nitric Oxide Pathway.

Authors:  Taylor Claybaugh; Sarah Decker; Kelly McCall; Yuriy Slyvka; Jerrod Steimle; Aaron Wood; Megan Schaefer; Jean Thuma; Sharon Inman
Journal:  Int J Endocrinol       Date:  2014-01-12       Impact factor: 3.257

9.  Renoprotective capacities of non-erythropoietic EPO derivative, ARA290, following renal ischemia/reperfusion injury.

Authors:  Willem G van Rijt; Gertrude J Nieuwenhuijs-Moeke; Harry van Goor; Petra J Ottens; Rutger J Ploeg; Henri G D Leuvenink
Journal:  J Transl Med       Date:  2013-11-13       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.